CBIO
Crescent Biopharma
CBIO
CBIO
76 hedge funds and large institutions have $90.4M invested in Crescent Biopharma in 2020 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 30 increasing their positions, 25 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
59% less capital invested
Capital invested by funds: $220M → $90.4M (-$129M)
86% less call options, than puts
Call options by funds: $2K | Put options by funds: $14K
Holders
76
Holding in Top 10
–
Calls
$2K
Puts
$14K
Top Buyers
| 1 | +$2.57M | |
| 2 | +$738K | |
| 3 | +$700K | |
| 4 |
Morgan Stanley
New York
|
+$471K |
| 5 |
Walleye Capital
New York
|
+$388K |
Top Sellers
| 1 | -$5.44M | |
| 2 | -$2.49M | |
| 3 | -$2.09M | |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$704K |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$344K |